[A25-97] Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V

Last updated 28.10.2025

Project no.:
A25-97

Commission:
Commission awarded on 29.07.2025 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Project no.	Title	Status
A24-87	Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-86	Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-138	Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-27	Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-30	Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-29	Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-31	Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-26	Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V	Commission completed
A20-87	Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-69	Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A25-96	Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V	Commission work started
A25-98	Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V	Commission work started

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form